Form 4: Supernus CFO Acquires Performance Share Units

Supernus Pharmaceuticals' Senior Vice-President and CFO, Timothy C. Dec, acquired 3,000 performance share units, which vested upon achievement of performance objectives.

Summary

• Timothy C. Dec, Senior Vice-President & CFO of Supernus Pharmaceuticals, Inc. (SUPN), acquired 3,000 Performance Share Units (PSUs).
• The PSUs were initially awarded on February 22, 2024.
• A portion of these PSUs vested upon the achievement of individual performance objectives, which were established on June 24, 2024.
• The reported transaction date for the acquisition/vesting of these units is February 28, 2026.
• Each Performance Share Unit is convertible into one share of Supernus Pharmaceuticals, Inc. common stock.
• Following this reported transaction, Timothy C. Dec beneficially owns 3,000 derivative securities in the form of Performance Share Units.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates executive compensation is tied to performance and aligns management's interests with shareholders, which is generally favorable for corporate governance and long-term value creation.

Positives

• The acquisition of Performance Share Units by a Senior Vice-President & CFO indicates alignment of management's interests with shareholder value.
• The vesting of these units is tied to the achievement of individual performance objectives, suggesting a performance-driven compensation structure that incentivizes executive performance.

Future Outlook

The vesting of the Performance Share Units on February 28, 2026, is contingent on the achievement of individual performance objectives, indicating a future-oriented incentive structure for the Senior Vice-President & CFO aimed at driving future company performance.

Management Comments

• "On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024."

Industry Context

StockSavvy.ai notes that performance-based equity awards are a standard practice in the pharmaceutical industry to incentivize executive performance and align their interests with long-term company success and shareholder returns. This type of compensation structure is widely adopted to motivate executives to achieve strategic goals and enhance company value.

Comparison to Industry Standards

• Performance Share Units (PSUs) are a common executive compensation tool across the pharmaceutical and biotechnology sectors, similar to practices at companies like Pfizer, Johnson & Johnson, and Merck, which also tie executive equity awards to specific financial or operational milestones.
• The structure, linking vesting to individual performance objectives, aligns with best practices for executive incentives aimed at driving specific strategic outcomes and fostering long-term value creation.

Stakeholder Impact

• Shareholders: Potential positive impact as executive compensation is aligned with performance, potentially leading to better long-term company performance and shareholder returns.

Next Steps

• The Performance Share Units are expected to convert into common stock on or after February 28, 2026, upon their vesting.

Key Dates

Recommendation

This Form 4 filing details a routine executive compensation event involving the vesting of performance share units. While it indicates alignment of management incentives with company performance, it does not present new information significant enough to warrant a change in investment recommendation. It's a standard disclosure, not a catalyst for a 'buy' or 'sell' decision, thus a 'hold' recommendation is appropriate for existing investors.

Keywords

Supernus Pharmaceuticals, SUPN, Timothy C. Dec, Form 4, insider transaction, performance share units, executive compensation, stock award